Vitro Biopharma, Inc. (VTRO)

Vitro Biopharma Income Statement

Financials in millions USD. Fiscal year is November - October.

Year Ending	TTM	Oct 31, 2021	Oct 31, 2020
Revenue	3.07	1.31	0.65
Revenue Growth (YoY)	-	102.09%	-
Cost of Revenue	-	0.35	0.22
Gross Profit	2.5	0.96	0.43
Selling, General & Admin	-	4.96	1.7
Research & Development	-	0.12	-
Operating Expenses	-	5.08	1.7
Operating Income	-3.18	-4.12	-1.27
Interest Expense / Income	0.32	0.4	0.29
Pretax Income	-5.24	-4.76	-1.64
Net Income	-4.2	-4.52	-1.56
Preferred Dividends	1.04	0.24	0.07
Net Income Common	-5.24	-4.76	-1.64
Free Cash Flow	-1.75	-1.03	-0.81
Gross Margin	81.52%	73.20%	66.55%
Operating Margin	-103.69%	-314.03%	-195.54%
Profit Margin	-170.83%	-362.91%	-252.43%
Free Cash Flow Margin	-56.97%	-78.66%	-124.13%
EBITDA	-4.7	-4.19	-1.19
EBITDA Margin	-153.45%	-319.89%	-183.39%
Depreciation & Amortization	0.21	0.16	0.15
EBIT	-4.91	-4.35	-1.34
EBIT Margin	-160.24%	-332.02%	-207.10%

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).